PUBLISHER: The Business Research Company | PRODUCT CODE: 1274655
PUBLISHER: The Business Research Company | PRODUCT CODE: 1274655
“Nuclear Medicine Diagnostics Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for nuclear medicine diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The nuclear medicine diagnostics market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Major players in the nuclear medicine diagnostics market are Cardinal Health Inc., GE HealthCare Technologies Inc., Lantheus, Bayer AG, Bracco Diagnostic Inc., NorthStar Medical Radioisotopes LLC, Eckert & Ziegler, Jubilant DraxImage Inc., PharmaLogic Holdings Corp., Institute of Isotopes Co. Ltd., SHINE Medical Technologies LLC, Global Medical Solutions LLC, Bracco Imaging SPA, Advanced Accelerator Applications, IBA Molecular Imaging, Mallinckrodt PLC., and Curium Pharma.
The global nuclear medicine diagnostics market is expected to grow from $5.92 billion in 2022 to $6.58 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The nuclear medicine diagnostics market is expected to grow to $9.82 billion in 2027 at a CAGR of 10.5%.
The nuclear medicine diagnostics market consists of sales of renal scan, bone scan, gallium scan, heart scan, brain scan and breast scan diagnostics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Nuclear medicine uses radioactive substances inside the body to diagnose illnesses or to target and remove diseased or damaged organs and tissue (for treatment). Nuclear medicine includes the use of radioactive drugs for research, therapeutic, and diagnostic purposes. Radioactive tracers are used in diagnostic nuclear medicine to visualize and/or measure the overall or local function of an organ.
North America was the largest region in the nuclear medicine diagnostics market in 2022. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main types of nuclear medicine diagnostics are SPECT radiopharmaceuticals and PET radiopharmaceuticals. A single-photon emission computerized tomography (SPECT) Radiopharmaceuticals refer to gamma-ray tomographic imaging methods that are used in nuclear medicine. The various applications involved are cardiology, thyroid, neurology, oncology and others and the end-users include hospitals and diagnostic centers and research institutes.
The increasing demand for nuclear medicine diagnostics is expected to propel the growth of the nuclear medicine diagnostics market going forward. Nuclear medicine uses radioactive substances inside the body to diagnose illnesses or to target and remove diseased or damaged organs and tissue (for treatment). The diagnostic uses of nuclear medicine are primarily in radiation and other life-taking treatments. The demand for nuclear medicine diagnostics is increasing due to benefits such as accurate results and better treatment decision making. For instance, in April 2022, according to a report published on nuclear medicine diagnostics by the World Nuclear Association, a UK-based international organization that promotes nuclear power, the annual number of nuclear medicine treatments exceeds 40 million, and the need for radioisotopes is rising at a rate of up to 5% every year. Also, 90% of the procedures involving radioisotopes in medicine take place in more than 10,000 hospitals used worldwide. Hence, increasing demand for nuclear medicine diagnostics is expected to propel the growth of the nuclear medicine diagnostics market.
Innovative product development is a key trend gaining popularity in the nuclear medicine diagnostics market. Major companies operating in the nuclear medicine diagnostics market are undergoing the development of innovative products to strengthen their position in the market. For instance, in December 2020, the Food and Drug Administration (FDA), a US-based association responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, and biological products, approved 68Gallium PSMA-11 (Ga 68 PSMA-11) - the first drug for PET (positron emission tomography) imaging men with prostate cancer, the third most frequent type of cancer in the United States, often have PSMA-positive lesion. This certification is anticipated to raise interest in 68Gallium, a PET imaging isotope that is currently in short supply.
In January 2022, Eckert & Ziegler, a Germany-based provider of isotope technology for medical, scientific and industrial use acquired Tecnonuclear SA for an undisclosed amount. This acquisition will enable Eckert & Ziegler to expand essential healthcare services in Brazil and throughout South America. Tecnonuclear SA is an Argentina-based nuclear medicine specialist company.
The countries covered in the nuclear medicine diagnostics market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides nuclear medicine diagnostics market statistics, including nuclear medicine diagnostics industry global market size, regional shares, competitors with nuclear medicine diagnostics market share, detailed nuclear medicine diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the nuclear medicine diagnostics industry. This nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.